Skip to main content
. 2011 Feb 18;6(2):e16596. doi: 10.1371/journal.pone.0016596

Table 2. Overlapping genes between different treatments.

Treatment/cells Rituximab vs. LT20 Anti-IgM vs. Anti-IgM-F (ab')2 Anti-IgM/F (ab)2 vs. anti-IgG Anti-BCR vs. anti-CD20
OciLy18 NA 312 102 NA
Z138 NA 246 181 NA
REC1 98* 977 768 89
SUDHL4 436 NA NA 342**

*Intersection of genes deregulated by rituximab, rituximab-F(ab')2 and LT20.

**Only anti-IgG antibody as anti-BCR treatment.